

October 22, 2024

| | |
|---|---|
| BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400 001 Scrip Code: 517562 Scrip ID: TRIGYN | National Stock Exchange of India Limited Exchange Plaza, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East) Mumbai - 400 051 Company Code: TRIGYN |
|---|---|

Subject: Update on Outcome of Board Meeting – held on August 14, 2024

Dear Sirs,

In continuation to our intimation relating to outcome of the Board Meeting held on August 14, 2024 on the same subject matter, and in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we would like to inform you that, the Board of Directors at its Meeting had inter alia, had considered and approved

1. Appointment of Additional Director in the capacity of Non-Executive Director

Appointment of Dr. Satyam Choudary Cherukuri (DIN: 01294234) as an Additional Director in the capacity of a Non-Executive Director in the Non-Promoter Category on the Board of the Company subject to the approval of the members in the ensuing Annual General Meeting and shall be liable to be retire by rotation.

As per the communication received from Stock Exchange, we had to confirm that the Appointee Dr Satyam Cherukuri also does not debarred from holding the office of a Director by virtue of any SEBI order or any other such authority as required under the circulars.

In this respect the updated Disclosure required pursuant to Regulation 30 of the Listing Regulations read with Para A of Part A of Schedule III to the Listing Regulations read with the SEBI Circular having reference no. CIR/CFD/CMD/4/2015 dated September 9, 2015, with regard to change in Directors and Key Managerial Personnel is attached as "**Annexure A**"

Kindly take the same on record.

Thanking you,
For Trigyn Technologies Limited

Mukesh Tank
Company Secretary
Membership No. FCS 9604

Trigyn Technologies Limited
27 SDF-1, SEEPZ, Andheri (East), Mumbai 400 096, India.
Phone: +91-22-6140-0909 | Email: ro@trigyn.com
www.trigyn.com | CIN: L72200MH1986PLC039341

Annexure A

As required under clause 7(C) of Schedule III read with Regulation 30 of SEBI (LODR) Regulations, 2015 and in connection with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 information attached as under: -

1. Appointment of Dr. Satyam Choudary Cherukuri (DIN: 01294234) as an Additional Non-Executive Director

| No. | Details of Event | Particulars of Event |
|-----|---|--|
| 1 | Reason for change viz. appointment, resignation, removal, death or otherwise | Appointment of Additional Non-Executive Director |
| 2 | Date of appointment/ cessation (as applicable) & term of appointment | August 14, 2024 |
| 3 | brief profile (in case of appointment); | Please find below the table |
| 4 | Disclosure of relationships between directors (in case of appointment of a director). | There is no relationship between any appointee Director and any existing Director. |
| 5 | Information pursuant to BSE Circular with ref. no. LIST/ COMP/ 14/ 2018-19 and NSE Circular NSE/CML/2018/24 ('Circulars') | Dr. Satyam Choudary Cherukuri is not debarred from holding the office of a Director by virtue of any SEBI order or any other such authority as required under the circulars. |

Brief Profile of Dr. Satyam Choudary Cherukuri

Dr. Satyam Cherukuri is an independent consultant for corporate strategy, board governance, and innovation. He served as the Chairman of Ness Technologies (NASDAQ: NSTC), Chairman of the Executive Council of The Conference Board, and on the boards of Sarnoff Corporation, New Jersey Technology Council, Orchid Biosciences (NASDAQ: ORCH), Locus Discovery, and Lamina Ceramics.

Dr. Cherukuri served as the President & CEO of Sarnoff Corporation, Princeton, NJ, prior to its merger with SRI International, Menlo Park, CA, in 2011. Sarnoff, previously known as RCA Laboratories, pioneered the color television, CMOS, diode lasers, HDTV and the world's digital video standards, LCDS, and other consumer electronics and was a leading innovation center for semiconductor, optoelectronics, and satellite communication technologies. Sarnoff was also an incubator for dozens of startups where Dr. Cherukuri managed the creation of Orchid Biosciences (NASDAQ: ORCH), Delsys Pharmaceuticals (acquired by Elan), Lamina Ceramics (high power LED lighting), Song Bird Medical (disposable hearing aids), Locus Discovery (computational drug discovery) and Insulet (continuous insulin delivery, NASDAQ: PODD).

Dr. Cherukuri has a Ph. D in Ceramics and M.S. in Glass Science from Alfred University, Alfred, NY, and a B. Tech in Ceramic Engineering from IIT BHU, India. He holds over 40 US and 30 international patents and published 12 scientific papers. His specific areas of scientific and engineering expertise

Trigyn Technologies Limited

27 SDF-1, SEEPZ, Andheri (East), Mumbai 400 096, India.

Phone: +91-22-6140-0909 | Email: ro@trigyn.com

www.trigyn.com | CIN: L72200MH1986PLC039341



are electronic materials, semiconductor packaging, microfluidics, and biocompatible nano materials.

He is often invited to conduct a seminar on Myths, Methods, and Ecosystems of Innovation.

Kindly take the same on record.

Thanking you,
For Trigyn Technologies Limited

Mukesh Tank
Company Secretary
Membership No. FCS 9604

Trigyn Technologies Limited

27 SDF-1, SEEPZ, Andheri (East), Mumbai 400 096, India.

Phone: +91-22-6140-0909 | Email: ro@trigyn.com

www.trigyn.com | CIN: L72200MH1986PLC039341